Melissa Baird, the Chief Operating Officer of Hims & Hers Health, Inc. (NYSE:HIMS), recently executed a series of stock ...

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

Unions that provide health benefits to nearly a half-million workers — including many in Ohio — have filed nearly identical ...

As generative AI continues to reshape the legal and corporate landscapes, actionable steps should now be at the forefront of crisis communication plans to help firms combat the rapid spread of ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...

The city of Greensboro has joined a national litigation campaign suing the nation's three largest pharmacy benefit managers and three largest insulin manufacturers with the goal of lowering insulin pr ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side ...

An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.

Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...

Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...